$LEN — AVOID 📊 | 6 MONTHS THESIS

$LEN — AVOID 📊 | 6 MONTHS THESIS 🧭 Conviction: MED Lennar Corporation, together with its subsidiaries, operates as a homebuilder primarily under the Lennar brand in the United States. 🎯 FQ2 FY2026 (ends May) | reported Jun 11 | Rev $7.9B | EPS $1.31 vs $1.23 🟢 💡 Consensus was too low, but the +6.5% beat still leaves annualized EPS of $5.24 and a 17.2x P/E — expensive for a cyclical homebuilder at a likely peak. The market appears to be overlooking macro headwinds and margin compression that will erode future earnings. 🏢 Business Quality: 5/10 📊 Valuation: rich — trailing P/E of 17.2x vs historical homebuilder range of 10–15x mid-cycle; EV/EBITDA likely elevated given typical debt loads; no margin of... 🔮 Catalyst: none identified within 6 months ⚖️ Avoid LEN — a modest beat doesn't fix a rich valuation, weak quant profile, and lack of catalysts; the risk/reward for longs is poor. 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/LEN0701

🧭 Conviction: MED